STOCK TITAN

Jasper Therapeutics (JSPR) 10-K Filings

JSPR NASDAQ

Here are the 10-K annual reports from Jasper Therapeutics, Inc. (JSPR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.

Rhea-AI Summary

Jasper Therapeutics files an amendment to its annual report to add detailed Part III disclosures on governance, executive pay, ownership and related-party transactions. The update does not change financial statements and instead refreshes information on directors, board committees and leadership roles, including CEO Jeet Mahal and Executive Chairperson Tom Wiggans.

The filing highlights 2025 compensation for senior executives, with Jeet Mahal earning a $498,000 salary, a $112,050 bonus and $679,549 in option awards, and CFO Herb Cross receiving similar pay levels. It also describes equity incentive plans, director retainers and options, severance and change-in-control protections, an insider trading policy that bans hedging and pledging, and a Nasdaq-compliant clawback policy for erroneously awarded incentive compensation.

Rhea-AI Summary

Jasper Therapeutics, Inc. files its annual report outlining progress on briquilimab, a monoclonal antibody targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The company highlights positive early-stage clinical data, a shift of resources away from stem cell transplant uses, and a strategy to build a focused mast cell therapeutics franchise.

Jasper holds worldwide rights to briquilimab under exclusive licenses from Amgen and Stanford, supported by patent families expected to expire in 2027 with newer applications potentially extending protection into the 2040s. The report also details regulatory pathways, manufacturing via Lonza, competitive landscape, and substantial ongoing funding needs with a history of operating losses and going-concern risk.